-- The market release by the Company of several new and important PCT-based products and applications, including the use of PCT to significantly enhance (hours to minutes) the important trypsin digestion phase required prior to protein identification by mass spectrometry
Richard T. Schumacher, Founder, President, and CEO of Pressure BioSciences, Inc. commented: "It has been said that gaining market acceptance for any new, cutting-edge technology always takes longer and is far more difficult than one would ever expect. PCT has been no exception. Although we believe that in many cases PCT offers greater safety, speed, reproducibility, convenience, and quality than other sample preparation methods, it has been difficult, thus far, to generate the level of interest we believe this technology will ultimately gain. However, I am pleased to report that interest in PCT and the PCT Sample Preparation System has grown steadily over the past two months. During this period, we have received significantly more requests for product information and on-site demonstrations, and have added significantly more Type A leads to our sales pipeline, than during any other comparable two month period since we initiated our commercialization plans in early 2007. This increased interest in our PCT product line has already manifested itself in record installations for a quarter, and we are not even halfway through August. This is certainly an exciting time for all stakeholders in Pressure BioSciences."
About Pressure BioSciences, Inc.
Pressure BioSciences, Inc. (PBI) is a publicly-traded company focused
on the development, and commercialization, of a novel, enabling technology
called pressure cycling technology (PCT). PCT uses cycles of hydrostatic
pressure between ambient and ultra-high levels (up to 35,000 psi and
greater) to control bio-molecular interactions. PBI currently holds 13 US
and 6 foreign patents covering
|SOURCE Pressure BioSciences, Inc.|
Copyright©2008 PR Newswire.
All rights reserved